Chemical and Biological Defense Program - Office of the Under ...
Chemical and Biological Defense Program - Office of the Under ...
Chemical and Biological Defense Program - Office of the Under ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
UNCLASSIFIED<br />
Exhibit P-5, Cost Analysis: PB 2014 <strong>Chemical</strong> <strong>and</strong> <strong>Biological</strong> <strong>Defense</strong> <strong>Program</strong> Date: April 2013<br />
Appropriation / Budget Activity / Budget Sub Activity:<br />
0300D: Procurement, <strong>Defense</strong>-Wide / BA 03: <strong>Chemical</strong>/<br />
<strong>Biological</strong> <strong>Defense</strong> / BSA 1: CBDP<br />
P-1 Line Item Nomenclature:<br />
MA0800 - JOINT BIO DEFENSE PROGRAM (MEDICAL)<br />
LI MA0800 - JOINT BIO DEFENSE PROGRAM (MEDICAL) UNCLASSIFIED<br />
<strong>Chemical</strong> <strong>and</strong> <strong>Biological</strong> <strong>Defense</strong> <strong>Program</strong> Page 9 <strong>of</strong> 17 P-1 Line #92<br />
Item Nomenclature (Item Number - Item<br />
Name, DODIC):<br />
JM8788 - NEXT GENERATION<br />
DIAGNOSTICS SYSTEM (NGDS)<br />
OCONUS laboratories operated by <strong>the</strong> Army, Navy <strong>and</strong> Air Force in coordination with <strong>the</strong> Armed Forces Health Surveillance Center. NGDS Increment 2 is intended to provide advanced diagnostics for<br />
biological pathogens <strong>and</strong> toxins, diagnostics for chemical <strong>and</strong> radiological exposures, <strong>and</strong> to provide capability to lower echelons <strong>of</strong> care.<br />
Justification: The FY14 NGDS program will procure 2 COTS components for NGDS Increment 1 Service Lab systems.<br />
RDT&E Code B Item: 0603884BP/Proj MB4; 0604384BP/Proj MB5; 0607384BP/Proj MB7<br />
MB4/NGDS: RDT&E FY11 <strong>and</strong> Prior - 1.581M; FY12 - 12.786M; FY14 - 19.322M; FY15 - 7.500M; FY16 - 13.358M; FY17 - 14.000M; FY18 - 12.000M<br />
MB5/NGDS: RDT&E ; FY13 - 9.827M; FY14 - 8.636M; FY15 - 6.318M; FY16 - 6.420M; FY17 - 6.420M; FY18 - 6.420M<br />
MB7/NGDS: RDT&E ; FY14 - 0.499M; FY15 - 13.414M; FY16 - 14.551M; FY17 - 9.816M; FY18 - 3.277M<br />
DEVELOPMENT/TEST STATUS AND MAJOR MILESTONES<br />
NGDS - CRP - Development <strong>and</strong> Implementation <strong>of</strong> Quality Initiatives, Validation <strong>Program</strong>, <strong>and</strong> Systems Engineering (Sep 2006 to Mar 2015)<br />
NGDS - CRP - ISO certification (Jun 2007 to Sep 2014)<br />
NGDS - Increment 1 MS A: Feb 2012<br />
NGDS - Conduct market research, CP planning <strong>and</strong> Source Selection (Feb 2012 to Dec 2012)<br />
NGDS - Increment 1 Competitive Prototyping Phase (Dec 2012 to Jun 2013)<br />
NGDS - Increment 1 Development <strong>and</strong> FDA approval <strong>of</strong> Anthrax/VHF assays (Jun 2013 to Mar 2015)<br />
NGDS - Increment 1 Tularemia <strong>and</strong> Plague IVD assay development (Mar 2015 to Dec 2015)<br />
NGDS - Increment 1 MS C: Jun 2015<br />
NGDS - Increment 2 MS A: Sep 2014<br />
NGDS - Increment 2 MS C: Sep 2018<br />
55